Harmony Biosciences Acquires Epygenix Therapeutics, Inc., Adding Late-Stage Epilepsy Franchise to Growing Pipeline of Innovative CNS Assets

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. META
4. SPY
5. IBM
6. MU
7. FDX
8. BLZE
9. NKE
10. PRIM

Go back to Harmony Biosciences Acquires Epygenix Therapeutics, Inc., Adding Late-Stage Epilepsy Franchise to Growing Pipeline of Innovative CNS Assets

Harmony Biosciences Holdings Inc. (HRMY) PT Raised to $37 at Raymond James

April 30, 2024 12:17 PM EDT

Raymond James analyst Danielle Brill raised the price target on Harmony Biosciences Holdings Inc. (NASDAQ: HRMY) to $37.00 (from $34.00) while maintaining a Outperform rating.

The analyst comments "Wakix 1Q sales of $154.6M (-8.2% q/q) slightly beat our $152.9M estimate (vs consensus $154.7M), and FY24 revenue guidance of... More